Ziv-Aflibercept
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Aug 9, 2019 → Dec 23, 2022
NCT ID
NCT03712904About Ziv-Aflibercept
Ziv-Aflibercept is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03712904. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03712904 | Phase 2 | Terminated |
| NCT00082823 | Phase 1 | Completed |
| NCT00083213 | Phase 1 | Completed |
| NCT00045266 | Phase 1 | Completed |
| NCT00036946 | Phase 1 | Completed |
Competing Products
20 competing products in Uveal Melanoma